The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Open accessAbstract
BACKGROUND: Type 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells and dependence on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in patients with type 1 diabetes, but interventions that might affect clinical progression before diagnosis are needed. METHODS: We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development of clinical disease. Patients were randomly assigned to a single 14-day course of teplizumab or placebo, and follow-up for progression to clinical type 1 diabetes was performed with the use of oral glucose-tolerance tests at 6-month intervals. RESULTS: A total of 76 participants (55 [72%] of whom were ≤18 years of age) underwent randomization - 44 to the teplizumab group and 32 to the placebo group. The median time to the diagnosis of type 1 diabetes was 48.4 months in the teplizumab group and 24.4 months in the placebo group; the disease was diagnosed in 19 (43%) of the participants who received teplizumab and in 23 (72%) of those who received placebo. The hazard ratio for the diagnosis of type 1 diabetes (teplizumab vs. placebo) was 0.41 (95% confidence interval, 0.22 to 0.78; P = 0.006 by adjusted Cox proportional-hazards model). The annualized rates of diagnosis of diabetes were 14.9% per year in the teplizumab group and 35.9% per year in the placebo group. There were expected adverse events of rash and transient lymphopenia. KLRG1+TIGIT+CD8+ T cells were more common in the teplizumab group than in the placebo group. Among the participants who were HLA-DR3-negative, HLA-DR4-positive, or anti-zinc transporter 8 antibody-negative, fewer participants in the teplizumab group than in the placebo group had diabetes diagnosed. CONCLUSIONS: Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Family history of autoimmune diabetes and personal or family history of allergic diseases or other autoimmune diseases increases the risk of autoimmune diabetes compared with the general population (78,79).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, anti-CD3 treatment (teplizumab) has been shown to induce long-term protection (currently up to six years) from T1D in at-risk individuals, but the mechanisms responsible for this long-term protection remain incompletely understood29,30”
From An autoimmune stem-like CD8 T cell population drives type 1 diabetes (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The CD3 monoclonal antibody teplizumab has been shown to delay progression to type 1 diabetes in high-risk individuals (429).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [429]
The cited source says what the claim attributes to it.
In the citing paper
“there is now evidence that the anti-CD3 monoclonal antibody teplizumab delays progression to type 1 diabetes in high-risk individuals (429).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [429]
The cited source says what the claim attributes to it.
In the citing paper
“In one 2019 study with a 2year delay, annualised rates of clinical diabetes were 15% in the teplizumab group and 36% in the placebo group (table 1). 18”
From The future of type 1 diabetes therapy (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Teplizumab delays the onset of clinical type 1 diabetes by a median of 24 months.18”
From The future of type 1 diabetes therapy (2025) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019
(2018) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,855
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 2×
“Three participants in the teplizumab group and 4 participants in the placebo group did not complete the trial regimen; the reasons were laboratory abnormalities (4 participants), an inability to have intravenous access established (2), or rash (1).”
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,000
Cefalu, W. T., Andersen, D. K., Arreaza-Rubín, G., Pin, C. L., Sato, S. M., Verchere, C. B., Woo, M., & Rosenblum, N. D. (2021) · Diabetes Care · doi:10.2337/dci21-0051 · Cited by 36
Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes
Rathod, S. (2022) · Diabetology · doi:10.3390/diabetology3010007 · Cited by 33
Zhong, T., Li, X., Lei, K., Tang, R., Deng, Q., Love, P. E., Zhou, Z., Zhao, B., & Li, X. (2024) · Nature Communications · doi:10.1038/s41467-024-53264-8 · Cited by 38
The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
Carballido, J. M., Regairaz, C., Rauld, C., Raad, L., Picard, D., & Kammuller, M. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00472 · Cited by 35
Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
Torun, A., Hupalowska, A., Trzonkowski, P., Kierkuś, J., & Pyrzyńska, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642166 · Cited by 40
Rueda, M. P. C., Raftopoulou, A., Gögele, M., Borsche, M., Emmert, D. B., Fuchsberger, C., Hantikainen, E. M., Vuković, V., Klein, C., Pramstaller, P. P., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.706145 · Cited by 33
Bonifacio, E. E., & Ziegler, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16354 · Cited by 35
Self-citationEnteroviruses and T1D: Is It the Virus, the Genes or Both which Cause T1D
Geravandi, S., Liu, H., & Maedler, K. (2020) · Microorganisms · doi:10.3390/microorganisms8071017 · Cited by 33
Molecular Footprints of the Immune Assault on Pancreatic Beta Cells in Type 1 Diabetes
Colli, M. L., Szymczak, F., & Eizirik, D. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.568446 · Cited by 33
A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care
Greenbaum, C. J. (2021) · Diabetes · doi:10.2337/db20-1112 · Cited by 34
Self-citationCabrera, S. M., Coren, A. T., Pant, T., Ciecko, A. E., Jia, S., Roethle, M. F., Simpson, P. M., Atkinson, S. N., Salzman, N. H., Chen, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07203-6 · Cited by 34
Chitnis, T., Kaskow, B. J., Case, J., Hanus, K., Li, Z., Varghese, J. F., Healy, B. C., Gauthier, C. D., Saraceno, T. J., Saxena, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956907 · Cited by 33
Rosselot, C., Li, Y., Wang, P., Alvarsson, A., Beliard, K., Lu, G., Kang, R. B., Li, R., Liu, H., Gillespie, V., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3456 · Cited by 30
He, Z., Glass, M. C., Venkatesan, P., Feser, M. L., Lazaro, L., Okada, L. Y., Tran, N. T. T., He, Y. D., Zaim, S. R., Bennett, C., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adt7214 · Cited by 31
Pharmacological Targeting of Endoplasmic Reticulum Stress in Pancreatic Beta Cells
Bilekova, S., Sachs, S., & Lickert, H. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.011 · Cited by 31
Admin, A., Calvo, T. R., Krogvold, L., Amirian, N., Dahl‐Jørgensen, K., & von Herrath, M. (2021) · Diabetes · doi:10.2337/db20-0908 · Cited by 32
Ghalwash, M. F., Anand, V., Lou, O., Martin, F., Rewers, M., Ziegler, A., Toppari, J., Hagopian, W., Veijola, R., Achenbach, P., et al. (2023) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00350-9 · Cited by 36
Self-citationLNP-mRNA vaccine prevents type 1 diabetes in non-obese diabetes mice
Chen, J., Hu, Y., Chen, Y., Zhou, Z., Shen, Y., Wang, Y., Liu, Z., Li, X., Su, Z., & Wu, J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.020 · Cited by 30
Grännö, O., Bergemalm, D., Salomon, B., Lindqvist, C. M., Hedin, C. R. H., Carlson, M., Dannenberg, K., Andersson, E., Keita, Å. V., Magnusson, M. K., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.11.006 · Cited by 30
Speake, C., Ylescupidez, A., Neiman, D., Shemer, R., Gläser, B., Tersey, S. A., Usmani‐Brown, S., Clark, P. L., Wilhelm, J. J., Bellin, M. D., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa008 · Cited by 30
Self-citationRapini, N., Schiaffini, R., & Fierabracci, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062103 · Cited by 31
Sosenko, J. M., Skyler, J. S., Herold, K. C., Schatz, D., Haller, M. J., Pugliese, A., Cleves, M. A., Geyer, S. M., Rafkin, L. E., Matheson, D., et al. (2020) · Diabetes · doi:10.2337/db20-0166 · Cited by 30
Self-citationIslet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes
Balmas, E., Chen, J., Hu, A. K., DeBerg, H. A., Rosasco, M. G., Gersuk, V. H., Serti, E., Speake, C., Greenbaum, C. J., Nepom, G. T., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.167881 · Cited by 30
Self-citationKishimoto, T., Fournier, M., Michaud, A. M., Rizzo, G. L., Roy, C. J., Capela, T., Nukolova, N. V., Li, N., Doyle, L., Fu, F.-N., et al. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103125 · Cited by 38
Understanding Islet Autoantibodies in Prediction of Type 1 Diabetes
Jia, X., & Yu, L. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad160 · Cited by 33
Kurppa, K., Mulder, C. J. J., Størdal, K., & Kaukinen, K. (2024) · Gastroenterology · doi:10.1053/j.gastro.2023.12.026 · Cited by 32
Persistence of islet autoantibodies after diagnosis in type 1 diabetes
Long, A. E., George, G., & Williams, C. L. (2021) · Diabetic Medicine · doi:10.1111/dme.14712 · Cited by 29
Beta Cell Therapies for Preventing Type 1 Diabetes: From Bench to Bedside
Brawerman, G. M., & Thompson, P. J. (2020) · Biomolecules · doi:10.3390/biom10121681 · Cited by 29
The role of the interferon/JAK-STAT axis in driving islet HLA-I hyperexpression in type 1 diabetes
Russell, M. A., Richardson, S. J., & Morgan, N. G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1270325 · Cited by 28
Cobo‐Vuilleumier, N., & Gauthier, B. R. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154137 · Cited by 25
Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus
Robinson, S., & Thomas, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654701 · Cited by 29
From Pancreatic β-Cell Gene Networks to Novel Therapies for Type 1 Diabetes
Eizirik, D. L., Szymczak, F., Alvelos, M. I., & Martin, F. (2021) · Diabetes · doi:10.2337/dbi20-0046 · Cited by 28
Boltri, J. M., Tracer, H. L., Strogatz, D. S., Idzik, S. R., Schumacher, P., Fukagawa, N. K., Leake, E., Powell, C., Shell, D., Wu, S. S., et al. (2023) · Diabetes Care · doi:10.2337/dc22-0620 · Cited by 31
Lessons and gaps in the prediction and prevention of type 1 diabetes
Mameli, C., Triolo, T. M., Chiarelli, F., Rewers, M., Zuccotti, G., & Simmons, K. M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106792 · Cited by 33
Quantifying beta cell function in the preclinical stages of type 1 diabetes
Galderisi, A., Carr, A. L. J., Martino, M., Taylor, P., Senior, P. A., & Dayan, C. M. (2023) · Diabetologia · doi:10.1007/s00125-023-06011-5 · Cited by 31
Patil, A. R., Schug, J., Liu, C., Lahori, D., Descamps, H. C., Naji, A., Kaestner, K. H., Faryabi, R. B., & Vahedi, G. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101535 · Cited by 30
Yang, K., Zhang, Y., Ding, J., Li, Z., Zhang, H., & Zou, F. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1377322 · Cited by 30
Type 1 diabetes mellitus prevention: present and future
Henriques, F. L., Buckle, I., & Forbes, J. M. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01128-6 · Cited by 32
Jacobsen, L. M., & Schatz, D. (2026) · JAMA · doi:10.1001/jama.2026.0048 · Cited by 30
Self-citationTherapeutic Strategies for Diabetes: Immune Modulation in Pancreatic β Cells
Jo, S., & Fang, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.716692 · Cited by 30
Charles, M. A., & Leslie, R. D. (2021) · Diabetes · doi:10.2337/dbi21-0012 · Cited by 27
Fyvie, M. J., & Gillespie, K. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1158278 · Cited by 29
Rampelbergh, J. V., Achenbach, P., Leslie, R. D., Ali, M. A., Dayan, C. M., Keymeulen, B., Owen, K. R., Kindermans, M., Parmentier, F., Carlier, V. A., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02900-z · Cited by 28
Tolerogenic dendritic cells in type 1 diabetes: no longer a concept
Giannoukakis, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212641 · Cited by 25
Sims, E. K., Geyer, S. M., Long, S. A., & Herold, K. C. (2023) · Diabetologia · doi:10.1007/s00125-023-06003-5 · Cited by 28
Self-citationA standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes
Ylescupidez, A., Bahnson, H. T., O’Rourke, C., Lord, S. M., Speake, C., & Greenbaum, C. J. (2023) · Nature Communications · doi:10.1038/s41467-023-42581-z · Cited by 29
Self-citationHealth economic considerations of screening for early type 1 diabetes
Rewers, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16522 · Cited by 27
Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report
Lin, A., Mack, J. A., Bruggeman, B., Jacobsen, L. M., Posgai, A. L., Wasserfall, C. H., Brusko, T. M., Atkinson, M. A., Gitelman, S. E., Gottlieb, P. A., et al. (2021) · Diabetes · doi:10.2337/db20-1103 · Cited by 27
Self-citationHanna, S. J., Tatović, D., Thayer, T. C., & Dayan, C. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751701 · Cited by 25
Potential Therapeutic Application of Regulatory T Cells in Diabetes Mellitus Type 1
Beń‐Skowronek, I., Sieniawska, J., Pach, E., Wrobel, W., Skowronek, A., Tomczyk, Z., & Rosolowska, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010390 · Cited by 27
Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?
Deligne, C., You, S., & Mallone, R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12040542 · Cited by 26
Continuous Glucose Monitoring Profiles in Healthy, Nondiabetic Young Children
DuBose, S. N., Kanapka, L. G., Bradfield, B., Sooy, M., Beck, R. W., & Steck, A. K. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac060 · Cited by 27
Felton, J. L., Griffin, K., Oram, R. A., Speake, C., Long, S. A., Önengüt-Gümüşcü, S., Rich, S. S., Monaco, G. S. F., Evans‐Molina, C., DiMeglio, L. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00357-y · Cited by 27
Self-citation‘Atypical’ Parkinson's disease – genetic
Weißbach, A., Wittke, C., Kasten, M., & Klein, C. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.10.011 · Cited by 26
Dillon, C. F., Weisman, M. H., & Miller, F. W. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226516 · Cited by 29
Templeman, E. L., Ferrat, L. A., Thomas, N. J. M., Speake, C., Wherrett, D. K., Sherr, J. L., Wentworth, J. M., REDONDO, M. J., Parik, H. M., Felton, J. L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0192 · Cited by 25
Self-citationPancreatic β cell regeneration induced by clinical and preclinical agents
Wang, K., Tao, M., Wei, T., & Wei, R. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i1.64 · Cited by 27
Japp, A. S., Meng, W., Rosenfeld, A. M., Perry, D. J., Thirawatananond, P., Bacher, R. L., Liu, C., Gardner, J. S., Atkinson, M. A., Kaestner, K. H., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.035 · Cited by 25
Diabetes type 1: Can it be treated as an autoimmune disorder?
Vallianou, N. G., Stratigou, T., Geladari, E. V., Tessier, C. M., Mantzoros, C. S., & Dalamaga, Μ. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09642-4 · Cited by 28
Galderisi, A., Moran, A., Evans‐Molina, C., Martino, M., Santoro, N., Caprio, S., & Cobelli, C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab344 · Cited by 26
Self-citationGavin, J. R., & Bailey, C. J. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0211 · Cited by 25
The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes
Mader, J. K., Wong, J. C., Freckmann, G., Garcia‐Tirado, J., Hirsch, I. B., Johnson, S. B., Kerr, D. E., Kim, S. H., Lal, R., Montaser, E., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251333441 · Cited by 27
Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes
Mignogna, C., Maddaloni, E., D’Onofrio, L., & Buzzetti, R. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2022119 · Cited by 24
Possible heterogeneity of initial pancreatic islet beta‐cell autoimmunity heralding type 1 diabetes
Lernmark, Å., Akolkar, B., Hagopian, W., Krischer, J. P., McIndoe, R., Rewers, M., Toppari, J., Vehik, K., Ziegler, A., & The TEDDY Study Group (2023) · Journal of Internal Medicine · doi:10.1111/joim.13648 · Cited by 26
Self-citationAutoimmunity to tetraspanin-7 in type 1 diabetes
McLaughlin, K. A., Tombs, M. A., & Christie, M. R. (2020) · Medical Microbiology and Immunology · doi:10.1007/s00430-020-00674-2 · Cited by 25
New therapeutic approaches for type 1 diabetes: Disease-modifying therapies
Nagy, G., Szekely, T. E., Somogyi, A., Herold, M., & Herold, Z. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i10.835 · Cited by 23
Vivas, Á. J., Boumediene, S., & Tobón, G. J. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103611 · Cited by 25
Desouter, A. K., Keymeulen, B., de Velde, U. V., Dalem, A. V., Lapauw, B., Block, C. E. M. D., Gillard, P., Seret, N., Balti, E. V., Vooren, E. R. V., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2376 · Cited by 23
New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond
Sabatino, J. J., Cree, B., & Hauser, S. L. (2025) · Annals of Neurology · doi:10.1002/ana.27270 · Cited by 27
Disparities in access to and use of diabetes technologies and therapeutics: a narrative review
Addala, A., Amedari, M. I., Figg, L. E., & Ebekozien, O. A. (2025) · Diabetologia · doi:10.1007/s00125-025-06494-4 · Cited by 24
Tolerance-inducing medicines in autoimmunity: rheumatology and beyond
Stanway, J. A., & Isaacs, J. D. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30100-4 · Cited by 23
Interactions between islets and regulatory immune cells in health and type 1 diabetes
Budd, M. A., Monajemi, M., Colpitts, S. J., Crome, S. Q., Verchere, C. B., & Levings, M. K. (2021) · Diabetologia · doi:10.1007/s00125-021-05565-6 · Cited by 26
Approaches to Establishing Tolerance in Immune Mediated Diseases
Huffaker, M. F., Sanda, S., Chandran, S., Chung, S. A., Clair, E. W. S., Nepom, G. T., & Smilek, D. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744804 · Cited by 25
Is Prevention the Best Way to Modify Inflammatory Bowel Disease? How Close Are We?
Torres, J., Ungaro, R. C., & Colombel, J.-F. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.07.051 · Cited by 23
Immunotherapy for type 1 diabetes
Allen, L. A., & Dayan, C. M. (2021) · British Medical Bulletin · doi:10.1093/bmb/ldab027 · Cited by 24
Anderson, R. L., DiMeglio, L. A., Mander, A., Dayan, C. M., Linsley, P. S., Herold, K. C., Marinac, M., & Ahmed, S. T. (2022) · Diabetes Care · doi:10.2337/dc22-0308 · Cited by 24
Self-citationDing, J., Yang, K., Lin, K.-L., Cao, Y.-K., & Zou, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1090842 · Cited by 25
3D Bioprinting and Translation of Beta Cell Replacement Therapies for Type 1 Diabetes
Gurlin, R. E., Giraldo, J. A., & Latres, E. (2020) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2020.0192 · Cited by 23
Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells
Leung, S. S., Borg, D. J., McCarthy, D. A., Boursalian, T. E., Cracraft, J., Zhuang, A., Fotheringham, A. K., Flemming, N., Watkins, T. S., Miles, J. J., et al. (2022) · Diabetes · doi:10.2337/db22-0177 · Cited by 23
Teplizumab in Relatives at Risk for Type 1 Diabetes
Herold, K. C., Bundy, B. N., & Krischer, J. P. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1912500 · Cited by 23
Self-citationHalperin, I. J., Wicklow, B., Amed, S., Chambers, A., Courage, C., Cummings, E., Kirkland, P., MacKay, D., Nakhla, M., Punthakee, Z., et al. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.01.001 · Cited by 22
Garcia-Loza, I., Perna‐Barrull, D., Aguilera, E., Almenara‐Fuentes, L., Gómez-Muñoz, L., Greco, D., Vila, M., Salvadó, M., Mancera-Arteu, M., Olszowy, M. W., et al. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103196 · Cited by 22
A microRNA-based dynamic risk score for type 1 diabetes
Joglekar, M. V., Wong, W. K. M., Kunte, P. S., Hardikar, H. P., Kulkarni, R. A., Ahmed, I., Farr, R. J., Pham, N. H. T., Coles, M., Kaur, S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03730-7 · Cited by 22
Self-citationEvans‐Molina, C., Dor, Y., Lernmark, Å., Mathieu, C., Millman, J. R., Mirmira, R. G., Pociot, F., REDONDO, M. J., Rich, S. S., Richardson, S. J., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06462-y · Cited by 28
Autoantigens in rheumatoid arthritis and the potential for antigen-specific tolerising immunotherapy
Nel, H. J., Malmström, V., Wraith, D. C., & Thomas, R. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30344-1 · Cited by 22
Parent and Pediatrician Preferences for Type 1 Diabetes Screening in the U.S.
Dunne, J. L., Koralova, A., Sutphin, J., Bushman, J. S., Fontanals-Ciera, B., Coulter, J., Hutton, C. T., Rewers, M., & Mansfield, C. A. (2020) · Diabetes Care · doi:10.2337/dc20-0927 · Cited by 25
Anti-inflammatory and Immunomodulatory Therapies in Atherosclerosis
Deroissart, J., Porsch, F., Köller, T., & Binder, C. J. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_505 · Cited by 24
Moreira, T. G., Matos, K. T. F., Paula, G. S. D., Santana, T. M. M., Mata, R. G. D., Pansera, F. C., Cortina, A. S., Spinola, M. G., Baecher‐Allan, C., Keppeke, G. D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.709861 · Cited by 19
A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes
Marwaha, A., Chow, S., Pesenacker, A. M., Cook, L. E., Sun, A. C., Long, S. A., Yang, J. H. M., Ward‐Hartstonge, K. A., Williams, E., Domingo‐Vila, C., et al. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab022 · Cited by 25
Self-citationLeFevre, J., Cyriac, S. L., Tokmic, A., & Pitlick, J. M. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac244 · Cited by 22
Cherubini, V., & Chiarelli, F. (2023) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-023-01438-3 · Cited by 26
Therapeutic tactics for targeting B lymphocytes in autoimmunity and cancer
Wemlinger, S. M., & Cambier, J. C. (2023) · European Journal of Immunology · doi:10.1002/eji.202249947 · Cited by 23
Nitecki, M., Gerstein, H. C., Balmakov, Y., Tsur, E., Babushkin, V., Michaeli, T., Afek, A. B., Pinhas‐Hamiel, O., Cukierman‐Yaffe, T., & Twig, G. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02007-y · Cited by 27
McGrail, C., Chiou, J., Egamal, R., Luckett, A. M., Oram, R. A., Benaglio, P., & Gaulton, K. J. (2024) · Diabetes Care · doi:10.2337/dc24-1251 · Cited by 22
Diabetes mellitus polygenic risk scores: heterogeneity and clinical translation
Ortega, H. I., Udler, M. S., Gloyn, A. L., & Sharp, S. A. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01132-w · Cited by 26
Vincentini, O., Pricci, F., Silano, M., Agrimi, U., Iacoponi, F., Villa, M., Porfilio, C., Sedile, A. I., Ulivi, F., Catassi, C., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328624 · Cited by 24
Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab
Mathieu, C., Sims, E. K., Chatenoud, L., James, E. A., Atkinson, M. A., & Herold, K. C. (2025) · Diabetes Care · doi:10.2337/dci25-0066 · Cited by 23
Self-citationThe Multifactorial Progression from the Islet Autoimmunity to Type 1 Diabetes in Children
Bauer, W., Gyenesei, A., & Kretowski, A. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147493 · Cited by 25
Sims, E. K., Cuthbertson, D. D., Herold, K. C., & Sosenko, J. M. (2021) · Diabetes · doi:10.2337/db21-0519 · Cited by 22
Self-citationCefalu, W. T., Andersen, D. K., Arreaza-Rubín, G., Pin, C. L., Sato, S. M., Verchere, C. B., Woo, M., & Rosenblum, N. D. (2021) · Diabetes · doi:10.2337/db21-0777 · Cited by 20
Metadata
- Authors
- Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., Marks, J. B., Moore, W., Moran, A., Rodriguez, H., Russell, W. E., Schatz, D., Skyler, J. S., Tsalikian, E., Wherrett, D. K., Ziegler, A.-G., & Greenbaum, C. J.
- Affiliations
- University of Miami (US)
- Children's Mercy Hospital (US)
- University of Minnesota (US)
- University of Iowa (US)
- ORCID
- Herold, Kevan C.
- Bundy, Brian N.
- Long, S. Alice
- Bluestone, Jeffrey A.
- DiMeglio, Linda A.
- Dufort, Matthew J.
- Gitelman, Stephen E.
- Gottlieb, Peter A.
- Krischer, Jeffrey P.
- Linsley, Peter S.
- Marks, Jennifer B.
- Moran, Antoinette
- Rodriguez, Henry
- Russell, William E.
- Schatz, Desmond
- Skyler, Jay S.
- Tsalikian, Eva
- Wherrett, Diane K.
- Ziegler, Anette-Gabriele
- Greenbaum, Carla J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-15
- Volume
- 381
- Issue
- 7
- Pages
- 603-613
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6776880
- OpenAlex
- W2948104235
- Semantic Scholar
- a5198a4024a6f0aecc74d1501dd9fd2892f98796
- Cited by
- 1,189
- References
- 48
- Citations by year
- 2026: 186 · 2025: 209 · 2024: 211 · 2023: 181 · 2022: 123 · 2021: 148 · 2020: 98 · 2019: 32
- FWCI
- 60.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085461, U01 DK085465, U01 DK085466, U01 DK085476, U01 DK085499, U01 DK085509, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK107013, U01 DK107014, UC4 DK085466, UC4 DK097835, UC4 DK106993)
- JDRF
- American Diabetes Association
- The Immune Tolerance Network (UM1 AI09565)
- National Center for Research Resources, through Clinical Translational Science Awards (UL1TR000064, UL1TR000114, UL1TR000142, UL1TR000445, UL1TR001082, UL1TR001857, UL1TR001872, UL1TR002366, UL1TR002529, UL1TR002537)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- teplizumab, anti-CD3 monoclonal antibody, type 1 diabetes prevention, high-risk relatives, TIGIT, HLA-DR3, HLA-DR4, zinc transporter 8 antibodies, islet autoimmunity, lymphopenia
- MeSH terms
- Adolescent, Adult, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Exanthema, Female, Glucose Tolerance Test, Humans, Lymphopenia, Male, Middle Aged, T-Lymphocytes, HLA-DR3 Antigen, HLA-DR4 Antigen, Proportional Hazards Models, CD3 Complex, Disease Progression, Lymphocyte Count, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
